Yahoo Finance

ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on SPRY:

• ARS Pharmaceuticals adds neffy to Commercial national formularies

• ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia

• ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia

• ARS Pharmaceuticals announces planned launch of neffyinSchools

• ARS Pharmaceuticals’ Strong Q3 2024 Highlights